Meda Pharmaceuticals in Canada has announced that Health Canada has approved Dymista azelastine hydrochloride/fluticasone propionate nasal spray for the treatment of moderate-to-severe seasonal allergic rhinitis for patients age 12 years old and older who do not achieve sufficient symptom relief with either antihistamines or intranasal corticosteroids.
Dymista has apparently been available in Canada since the beginning of September, 2015:
https://twitter.com/lee_jasonk/status/639491186214981636
In the US, the FDA approved Dymista for the treatment of seasonal allergic rhinitis in patients 12 and older in May 2012 and for children aged 6-11 in February 2015. In Europe, Dymista was approved in January 2013.
Read the Meda press release.
